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The  discovery  of  α-synuclein  (αs)  mutations  has  made  a  major  contribution  to  the 
understanding of the pathogenesis of α-synucleinopathies such as Parkinson’s disease and 
dementia with Lewy bodies (DLB). In contrast, less attention has been paid to β-synuclein (βs) 
mutations. In this paper, we show that transgenic (tg) mice expressing DLB-linked P123H βs 
develop progressive neurodegeneration, as characterized by axonal swelling, astrogliosis and 
behavioural abnormalities, with memory disorder being more prominent than motor deficits. 
Furthermore, cross-breeding of P123H βs tg mice with αs tg mice, but not with αs knockout 
mice, greatly enhanced neurodegeneration phenotypes. These results suggest that P123H βs 
is pathogenic and cooperates with pathogenic αs to stimulate neurodegeneration in mouse 
brain, indicating a causative role of P123H βs in familial DLB. Given the neuritic pathology 
of βs in sporadic α-synucleinopathies, it appears that alteration of βs can contribute to the 
pathogenesis of a broad range of α-synucleinopathies. 
1 Division of Chemistry and Metabolism, Tokyo Metropolitan Institute for Neuroscience, Tokyo 183-8526, Japan. 2 Division of Gene Regulation and Signal  
Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama 350-1241, Japan. 3 Transgenic Animal Research Center, National   
Institute of Agrobiological Sciences, Tsukuba, Ibaraki 305-8634, Japan. 4 Department of Neurosciences, University of California-San Diego, La Jolla, California  
92093-0624, USA. 5 Division of Genetics, Department of Pediatrics, University of California-San Diego, La Jolla, California 92093-0624, USA. 6 Department  
of Cellular and Molecular Medicine, University of California-San Diego, La Jolla, California 92093-0624, USA. 7 Division of Biological Sciences, University of  
California-San Diego, La Jolla, California 92093-0624, USA. 8 Institute for Genomic Medicine, University of California-San Diego, La Jolla, California 92093-0624, USA.  
9 Rady Children’s Hospital, San Diego, California 92193, USA. 10 Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, 
Tokyo 113-8655, Japan. Correspondence and requests for materials should be addressed to M.H. (email: hashimoto-mk@igakuken.or.jp). 
A β-synuclein mutation linked to dementia 
produces neurodegeneration when expressed  
in mouse brain
masayo Fujita1, shuei sugama1, Kazunari sekiyama1, Akio sekigawa1, Tohru Tsukui2, masaaki nakai1,  
masaaki Waragai1, Takato Takenouchi1,3, Yoshiki Takamatsu1, Jianshe Wei1, Edward Rockenstein4,  
Albert R. Laspada5,6,7,8,9, Eliezer masliah4, satoshi Inoue2,10 & makoto Hashimoto1ARTICLE

nATuRE CommunICATIons | DoI: 10.1038/ncomms1101
nATuRE CommunICATIons | 1:110 | DoI: 10.1038/ncomms1101 | www.nature.com/naturecommunications
© 2010 Macmillan Publishers Limited. All rights reserved.
β
-Synuclein (βS) is an abundant pre-synaptic phosphoprotein 
that is found in the brain and is homologous to α-synuclein 
(αS)1,2. Both proteins have been characterized on the basis of 
their native unfolded structures, but βS is distinct from αS in that 
βS lacks the majority of the hydrophobic non-amyloid-β compo-
nent of the Alzheimer’s disease amyloid region3,4. Because of the 
presence of this highly amyloidogenic non-amyloid-β component, 
αS is prone to self-aggregate and form toxic protofibrils, whereas 
βS is less prone to form insoluble aggregates5–7. Several lines of evi-
dence suggest that βS may have a protective role against α-synu-
cleinopathies. In support of this notion, overexpression of βS in 
αS transgenic (tg) mice by either crossing with βS tg mice or using 
virus-mediated transfer results in amelioration of neuropathology 
(such as formation of Lewy body-like inclusions) and motor func-
tion deficits7–9. Mechanistically, βS may directly inhibit aggrega-
tion and protofibrillar formation of αS, as demonstrated under 
cell-free conditions7,10,11. An alternative mechanism may include 
a role of lipids, as it has been shown that oligomerization of αS 
is dramatically enhanced by increasing the cellular levels of poly-
unsaturated fatty acids12, which was inhibited by polyunsaturated 
fatty acid-associated βS in mesencephalic cells13.
In  this  context,  it  is  of  note  that  two  missense  mutations  of 
βS, P123H and V70M, have been linked to familial and sporadic 
dementia with Lewy bodies (DLBs), respectively14. It is possible that 
the DLB-linked βS mutants might have lost protective functions 
against the neurotoxicity caused by αS14. However, given the auto-
somal dominant trait of patients with the P123H mutation14, toxic 
gains of function of βS through gene mutation might contribute to 
the pathogenesis of familial DLB. In support of the latter possibility, 
our recent study showed that both P123H- and V70M-recombinant 
βS proteins were prone to aggregate in vitro and that expression of 
these mutant βS proteins in neuroblastoma cells resulted in lyso-
somal pathology associated with protein aggregation15,16.
Although DLB is the second most common cause of dementia 
after  Alzheimer’s  disease17,  the  pathogenic  mechanism  of  DLB  is 
poorly understood. Elucidation of the mechanism through which   
DLB-linked βS mutations cause neurodegeneration in vivo may pro-
vide us with some insights into this critical issue. Accordingly, the 
main objective of this study was to investigate the neuropathology of 
DLB-linked P123H βS through analysis of tg mice. The results show 
that tg mice expressing P123H βS were characterized by neuritic 
pathology, associated with astrogliosis and behavioural abnormali-
ties. Furthermore, the neuropathology of P123H βS tg mice was not 
significantly affected by cross-breeding with αS knockout (KO) mice. 
On the other hand, cross-breeding of P123H βS tg mice with αS tg 
mice resulted in enhanced phenotypes, including neuronal cell loss 
and dopaminergic dysfunction. These results strongly suggest that 
P123H βS is by itself pathogenic and cooperates with pathogenic αS 
to stimulate neurodegeneration.
Results
Neuropathological  characterization  of  P123H  βS  tg  mice.  We 
generated tg mice overexpressing P123H βS under the control of 
the Thy-1 promoter (Fig. 1a,b). In all lines of tg mice with P123H 
βS mRNA expression in the brain (Fig. 1c), P123H βS expression 
was also detected at the protein level (Fig. 1d). Mice from line C 
had the highest levels of transgene expression, followed by the two 
intermediate expressers, lines B and G, and the three low expressers, 
lines A, D and E. Lines C and B were analysed in the majority of 
experiments.
Histopathological  analyses  revealed  that  P123H  βS  mice  are 
characterized by extensive neuritic pathology. For instance, P123H 
βS accumulated in various brain regions as early as 6 months of age, 
including in apical dendrites in the cortex and in axonal deposits in 
the hippocampus (Fig. 2a). Given the lack of βS immunoreactivity for 
Lewy bodies formed in the autopsy brain with P123H βS mutation14,  
it  was  not  unexpected  that  Lewy  body-like  inclusions  were  not 
observed in P123H βS tg mice. However, one prominent feature   
of  these  mice  was  the  formation  of  P123H  βS-immunoreactive 
axonal  swellings  in  the  striatum  and  globus  pallidus  (Fig.  2b). 
The number of swellings was well correlated with the expression 
level of P123H βS and was observed in an age-dependent manner   
(Fig. 2b). Consistent with an abnormal accumulation of P123H βS, 
the same regions were accompanied by massive gliosis, as revealed 
by  an  increased  level  of  glial  fibrillary  acidic  protein  (GFAP)- 
positive astroglia (Supplementary Fig. S1a–c). In contrast to P123H 
βS mice, neither abnormal immunostaining of P123H βS nor gliosis 
was observed in both non-tg littermates and mice overexpressing 
wild-type (wt) βS (Fig. 2a–c, Supplementary Fig. S1a–c).
Electron  microscopy  (EM)  revealed  that  the  swellings  were 
‘globules’: small spheroids that are frequently associated with axonal   
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Figure 1 | Generation of P123H S tg mice. (a) scheme shows missense 
mutations of αs and βs identified in α-synucleinopathies. Two αs 
mutations, A30P45 and A53T46, were discovered in PD, and another αs 
mutation, E46K47, was later found in DLB. As for βs, two mutations, V70m 
and P123H, have been reported in DLB14. (b) Diagrammatic representation 
of the Thy-1–P123H βs construct. (c) northern blot analysis of P123H βs 
mRnA. Total RnA (10 µg) prepared from P123H βs tg (lines C, B, G, A, D 
and E) and non-tg (n) mice brains at 4 months was analysed by northern 
blotting using 32P-labelled P123H βs cDnA (upper panel). The filters were 
reprobed with 32P-actin cDnA (lower panel). Representative blots and 
data quantified against actin bands are shown as the mean ± s.e.m. (n = 3). 
Endogenous mouse βs mRnA was hardly detected with human P123H βs 
cDnA probe under the current experimental conditions. (d) Immunoblot 
analysis of P123H βs protein. Total brain extracts (10 µg) prepared from 
P123H βs tg (lines C, B, G, A, D and E) and non-tg (n) mice at 4 months 
were analysed using anti-P123H βs antibody, which recognizes P123H βs 
but not mouse wt βs (upper panel) (supplementary Table s2). The blots 
were reprobed with anti-βs antibody, which recognizes both P123H βs 
and mouse wt βs (middle panel) and anti-actin antibody (lower panel). 
Recombinant P123H βs (Rec.)15 was used as positive control. Representative 
blots and data quantified against actin bands are shown as the mean ± s.e.m. 
(n = 3). nAC, non-amyloid-β component.ARTICLE     
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dystrophy (Fig. 2d)18,19. The globules were composed of small vesicles 
and  frequently  contained  membranous  elements  such  as  multi-
vesicular bodies and multilayered membranes. Furthermore, the 
globules were surrounded by a single membrane with association 
of no myelin sheaths and no post-synaptic contacts, suggesting that 
these globules are not functional terminals. Moreover, LC3-positive 
dots were observed in the globules with an increased amount of 
LC3-II, a marker of autophagosomes20 (Supplementary Fig. S1d,e). 
Because cathepsins B and D activities, but not proteasome activi-
ties, were significantly decreased in P123H βS tg mice compared 
with non-tg littermates (Supplementary Fig. S1f–i), it is probable 
that autophagosomes might accumulate in the globules because of 
decreased clearance by lysosomes.
Notably,  double  immunofluorescence  study  showed  that  the 
P123H  βS-positive  globules  were  highly  immunoreactive  with 
anti-αS (~100%) and to a lesser extent with anti-ubiquitin (~70%) 
(Fig. 2e), indicating that endogenous αS and ubiquitinated pro-
teins  accumulated  because  of  compromised  degradation  at  the 
lysosome. A further study revealed that P123H βS-positive glob-
ules  were  also  immunostained  with  both  anti-γ-aminobutyric 
acid (anti-GABA) and antiglutamic acid decarboxylase antibodies 
(~100%; Fig. 2e). Although few GABAergic neurotransmitters in 
the basal ganglia, such as dynorphin, enkephalin and substance P, 
were detected in the globules, a weak immunoreactivity of calbi-
ndin was consistently detected (Supplementary Fig. S2), suggest-
ing that the globules were formed in projection-type GABAergic 
neurons.  Because  synaptic  markers  such  as  synaptophysin  and 
synapsin I and axonal markers including neurofilaments were not 
detectable (Supplementary Fig. S2), the results suggest again that 
these  GABAergic  neuronal  terminals  are  no  longer  functional. 
Degeneration of these neurons by P123H βS may be important, as 
there is ample evidence showing that GABAergic neurons in the 
striatum, which functions as the second component of the Par-
kinsonian circuit, are significantly altered in Parkinson’s disease 
(PD) brains21.
Consistent  with  the  histopathological  changes,  biochemical 
analyses showed that expression of P123H βS was increased in 
an age-dependent manner, particularly in formic acid (FA) frac-
tions, indicating a gradual accumulation of insoluble P123H βS 
(Supplementary Fig. S3a). Compared with P123H βS tg mice, no 
accumulation of wt βS was observed in FA fractions of wt βS tg 
mice (Supplementary Fig. S3b). Furthermore, upregulation of heat-
shock proteins (HSPs), including HSP70 and HSP25, was already 
apparent  at  6  months,  whereas  expression  of  synaptic  markers, 
such as SNAP25 and VAMP2, were decreased at 18 months, sug-
gesting that the protective capacity in P123H βS tg mice might be 
insufficient at this age (Supplementary Fig. S3c).
Finally, P123H βS tg mice exhibited various types of abnormal 
behaviours. To determine the effects of P123H βS accumulation 
on spatial learning and memory, a water maze test was conducted 
(Fig. 3). In the training sessions, P123H βS mice showed significant 
learning deficits, whereas non-tg controls performed normally 
(Fig. 3a). Furthermore, P123H βS mice showed significantly less 
preference for the target quadrant than non-tg littermates, sug-
gesting impaired retention of spatial memory (Fig. 3b,c). During 
the same stage, a home cage test demonstrated that various spon-
taneous activities were decreased in P123H βS tg mice (line C) 
compared with non-tg littermates (Fig. 3d). In contrast, a rotarod 
treadmill test showed that motor deficits were not observed in 
the middle stage (6 months) but became apparent during the late 
stage (12–18 months) in P123H βS tg mice (Fig. 3e).
Neuropathology of P123H S tg mice is not affected by deletion 
of S. The analysis of P123H βS tg mice unambiguously shows 
that P123H βS is pathogenic in mouse brain. However, it is unclear 
whether endogenous murine αS has any role in the neuropathology   
of P123H βS tg mice. This important question was addressed by a 
cross-breeding experiment of P123H βS tg with αS KO mice (Sup-
plementary Methods), in which various neurodegeneration pheno-
types,  including  neuritic  pathology  (Supplementary  Fig.  S4a), 
formation of globular axonal swelling (Supplementary Fig. S4b), 
protein aggregation (Supplementary Fig. S4c) and astrogliosis (Sup-
plementary Fig. S4d,e), were compared. The results showed that 
none of these neurodegenerative features were significantly differ-
ent between P123H βS and P123H βS/αS KO tg mice, indicating 
that endogenous αS may not be necessarily required for the neuro-
pathology of P123H βS.
Enhanced neuropathology in P123H βS/αS double tg mice. Next, 
a further cross-breeding experiment of P123H βS tg with αS-over-
expressing tg mice was conducted to assess the combined effects of 
P123H βS and pathogenic αS on neurodegeneration (Supplementary   
Methods). The neuropathological characterization of Thy-1 promoter-
driven αS-expressing tg mice was previously reported22, indicating 
that overexpressed αS is pathogenic in mouse brain. As we expected, 
bigenic mice overexpressing P123H βS and αS showed an enhanced 
neurodegenerative  phenotype  compared  with  each  monogenic  tg 
mouse. Besides lower body weight and high mortality (Supplemen-
tary Fig. S5a,b), bigenic mouse brains were characterized by increased 
protein aggregation, as demonstrated by the increased level of both 
αS and P123H βS in FA fractions (Supplementary Fig. S5c). Fur-
thermore, expression of synapse proteins, such as VAMP2, SNAP25 
and PSD95, was decreased in bigenic mice compared with litterma-
tes (Supplementary Fig. S5d). Moreover, various pro-inflammatory 
factors, including interleukin 1β (IL-1β), IL-6, tumour necrosis fac-
tor-α, induced nitrogen oxide synthase and monocyte chemotactic 
protein-1, were significantly upregulated in bigenic mice compared 
with littermates, suggesting that neuroinflammation was enhanced in 
bigenic mice (Supplementary Fig. S6a). Indeed, morphologically acti-
vated astrocytes and microglia were occasionally observed in bigenic 
mice but not in littermates (Supplementary Fig. S6b,c). Because IL-1β 
colocalized well with GFAP but not with CD11b, it was predicted that 
astrocytes may have a dominant role in inflammation in this stage 
(Supplementary Fig. S6d,e).
During the terminal stage (~9 months) of bigenic mice, numer-
ous phospho-c-Jun- and c-Fos-positive nuclei were observed in 
the hippocampus and cortex, suggesting that neurons in bigenic 
mice are subjected to chronic stress (Fig. 4a,b). Concordant with 
these findings, Fluoro Jade C (FJC)-positive degenerating neurons 
were occasionally observed in bigenic mice and to a lesser extent 
in αS tg mice (Fig. 4c). Given the immunoreactivity of αS in FJC-
positive  neurons,  accumulated  αS  might  directly  and  continu-
ously injure neurons, leading to stimulation of neurodegeneration   
(Fig. 4c). Such a chronic process of neurodegeneration may even-
tually lead to neuronal loss, as the numbers of NeuN-immuno-
positive  neurons  in  the  hippocampus  of  bigenic  mice  were   
significantly lower than those of monogenic tg mice and of non-
tg littermates (Fig. 4d). Nevertheless, terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL)-positive neurons 
were  not  convincingly  detected  (Fig.  4e),  suggesting  that  non-
apoptotic neuronal cell death may at least partly contribute to 
neuronal loss in bigenic mice. Similar TUNEL-negative neuronal 
death has been documented in various types of neurodegenera-
tion, including degeneration of dopaminergic neurons induced by 
6-hydroxydopamine,  axotomy  and  1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in adult mice23,24. Finally, EM studies 
consistently demonstrated the presence of degenerating dark neu-
rons in the hippocampus and cortex of bigenic brains, but not in 
littermates (Fig. 4f). Although the mechanism is unknown, dark 
neurons are induced under a variety of pathological conditions, 
including  ischaemia,  epilepsy  and  head  injury25.  Furthermore, 
dark neurons have been described in a mouse model and in the ARTICLE
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brain of a patient affected by Huntington’s disease26, as well as in 
an αS-conditioned mouse model of PD27 and in a MPTP-treated 
mouse model of PD28. Considering that conventional αS tg mice 
rarely exhibit neuronal death, our bigenic mice may be a powerful 
tool with which to investigate the mechanism of neuronal death in 
neurodegenerative diseases.
Finally, several findings suggested that dopaminergic dysfunction 
might be involved in motor dysfunctions of bigenic mice during the 
middle stage (4–7 months). First, strong clasping was observed in 
bigenic mice but not in other littermates (Fig. 5a). Clasping behav-
iour has never been observed in C57BL/6 mice during this stage in 
routine experiments. Furthermore, clasping has been described in 
various models of nigrostriatal anomalies29,30. Second, locomotor 
performance was significantly impaired in bigenic mice compared 
with αS tg mice and other littermates (Fig. 5b). Third, the levels 
of tyrosine hydroxylase (TH) and other dopaminergic markers, 
including L-dopa decarboxylase and dopamine transporter, were 
significantly decreased in the basal ganglia (Fig. 5c,d), although it 
was unclear whether the motor deficits were entirely attributable 
to  the  modest  decrease  (~40%)  in  the  dopamine  concentration 
(Fig. 5e). In addition, the number of globules in basal ganglia was 
significantly higher in bigenic mice compared with P123H βS mice 
(Supplementary Fig. S7). One may speculate that globule formation 
of GABAergic projection neurons was stimulated by the compen-
satory mechanism in response to decreased dopaminergic inputs 
in bigenic mice. Taken together, these results suggest that motor 
deficits of bigenic mice are attributed to axonal degeneration of 
nigrostriatal dopaminergic neurons.
Discussion
This study demonstrates that P123H βS is itself pathogenic, and 
endogenous murine αS is dispensable to the neuropathology of 
P123H βS tg mice. On the other hand, bigenic mice overexpress-
ing P123H βS and human αS exhibited enhanced neuropathology. 
These results strongly suggest that P123H βS may cooperate with 
the pathogenic (overexpressed) state of αS, but not with normal 
αS, to stimulate neurodegeneration. In this context, it is possible 
that aggregation of αS in the P123H βS brains of patients might be 
stimulated not only by P123H βS but also by other factors, such as 
ageing, genetic factors and environmental risks. Such a notion is in 
line with the incomplete dominant inheritance in a familial DLB 
associated with P123H βS mutation and could partly explain Lewy 
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Figure 2 | P123H S tg mice are characterized by a neuritic pathology. (a, b) Immunohistochemistry of P123H βs using anti-P123H βs antibody.  
In a, P123H βs accumulated in apical dendrites in the cortex (cort, left panels) and in axonal dots in the hippocampus (hippo, right panels) (6 and  
18 months (mo)) of P123H βs tg mice (line C, arrows), but not in the same regions of non-tg littermates (nonTg). scale bar = 10 µm. (b) Globules were 
observed in the striatum and globus pallidus of 18-month-old P123H βs tg mice (lines B and C, arrows), but not in non-tg littermates. scale bar = 10 µm.  
For quantification, five images were analysed for each mouse and the results were used to calculate the average number of globules per mm2. upper  
panel: multiple lines C, B, G, A, D and E, and non-tg (n) at 18 months; lower panel: lines B, C and n at 6, 12 and 18 months. Data are shown as the mean  
± s.e.m. (n = 7). (c) Immunohistochemistry of total βs using anti-βs antibody. βs accumulated in apical dendrites in the cortex (cort), and in axonal dots 
in the hippocampus (hippo) of 18-month-old P123H βs mice (lines C and B, arrows), but not in wt βs tg mice (wt βs-Tg) and non-tg littermates (nonTg). 
Arrowheads indicate negative staining of βs in apical dendrites. similarly, formation of globules in the striatum was observed in 18-month-old P123H 
βs mice (arrows), but not in age-matched wt βs tg mice and non-tg mice. scale bar = 20 µm. (d) Photomicrographs of two representative globules in 
18-month-old tg mice (line C). The lower two panels are insets from the two higher panels. Globules were composed of small vesicles and contained 
multivesicular bodies (arrows) and autophagosome-like multiple-layered membranous structures (arrowheads). scale bar = 1 µm (upper panel) and 
200 nm (lower panel). (e) Anti-P123H βs-immunopositive globules formed in the basal ganglia of P123H βs tg mice (line C, 18 months) were double 
stained with either anti-αs or anti-ubiquitin (ub) (upper six panels). Alternatively, anti-αs-immunopositive globules were stained with anti-αs and  
either anti-GABA or anti-glutamic acid decarboxylase (anti-GAD) (lower six panels). The slides were observed by laser scanning confocal microscopy. 
Arrows point to globules. scale bar = 10 µm.ARTICLE     
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body pathology in the postmortem brain of the patient14. It is also 
intriguing that the present results are in contrast to previous studies 
showing that neuropathological features of αS tg mice were amel-
iorated in bigenic mice overexpressing αS and wt βS7,8. Collectively, 
one possible interpretation is that the neuroprotective βS might be 
converted to a neurotoxic molecule by the P123H mutation, leading 
to stimulation of αS pathology.
The precise mechanism of neurotoxic conversion of βS by the 
P123H mutation is currently unknown. In this regard, it is of note 
that the C-terminal region of βS is composed of a polyproline II 
helix, unfolding of which may have an important role in protein–
protein interactions31. Thus, the P123H substitution may affect the 
polyproline II helix structure, resulting in a conformational change 
and misfolding of βS that leads to stimulation of αS oligomeriza-
tion. Because the C-terminal region of βS is subjected to post-trans-
lational modification through phosphorylation1 and glycosylation32, 
it is also possible that aberrant regulation of the C-terminal region 
by various stimuli may contribute to the involvement of βS in spo-
radic cases of α-synucleinopathies. Indeed, the neuritic pathology 
of P123H βS mice is reminiscent of previous reports showing that 
βS and γ-synuclein (γS), the third member of the synuclein fam-
ily  of  peptides,  are  associated  with  neuritic  pathology,  such  as 
in  dystrophic  neurites  and  spheroid  structures,  in  the  brains  of 
  sporadic cases of PD, DLB and neurodegeneration with brain iron 
  accumulation, type 133,34. Our findings and a recent report show-
ing that overexpression of γS results in neurodegeneration in mouse 
brain35 indicate the need for future studies to determine whether 
altered βS and possibly γS may cooperate with αS in the patho-
genesis of a broad range of α-synucleinopathies.
Methods
Summary of the generation and analysis of tg mice. All animal procedures were 
approved and conducted in accordance with Animal Ethics Review Committee 
regulations of the Tokyo Metropolitan Institute for Neuroscience.
For generation of tg mice expressing P123H βS, human P123H βS cDNA was 
released from a PCEP4-P123H βS vector15 and inserted into the XhoI site of the 
mouse Thy-1 expression cassette (kindly supplied by Dr H van der Putten, Ciba-
Geigy). The Thy-1-P123H βS plasmids were microinjected into fertilized eggs of 
C57BL/6 mouse and multiple lines of Thy-1-P123H βS tg mice were generated. 
Thy1-αS tg mice and Thy1-wt βS tg mice were both primarily established as DBA2 
× C57BL/6 hybrids7,22. These mice were maintained by successive (more than seven 
generations) backcrossing into the C57BL/6 strain. Heterozygote Thy1-P123H 
βS tg mice (line C: the highest expresser) were further crossed with heterozygote 
Thy1-αS tg mice to generate bigenic mice overexpressing human P123H βS and 
human αS, and littermates including P123H βS tg mice, αS tg mice and non-tg 
mice. Genomic DNA was extracted from tail biopsies, and genotyping of P123H 
βS and human αS was performed by PCR using specific primers (Supplementary 
Table S1). The tg mice were evaluated by histological and biochemical analyses 
using various antibodies (Supplementary Methods, Supplementary Table S2), in 
addition to several behavioural tests.
Tissue processing of tg mice brain. Mice brains were removed under deep an-
aesthesia and divided sagittally. One hemibrain was snap frozen in liquid nitrogen 
and stored at  − 80 °C for biochemical studies and RNA analysis. Hippocampus 
and cortex samples were collected from the region 1.8–2.8 mm posterior to the 
bregma, whereas striatum samples were obtained from the region 0–1 mm anterior 
to the bregma. The other hemibrain was fixed in Bouin’s solution and embedded in 
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Figure 3 | Behavioural abnormalities of P123H S tg mice. (a–c) The morris water maze test. Compared with non-tg littermates (nonTg), P123H βs 
tg mice (lines B and C) at 6 months (mo) did not show an improvement in performance during the training session (a). After removing the platform, a 
probe test was performed on the last day of the training session (b, c). P123H βs tg mice spent less time searching in the target quadrant than did non-Tg 
(n) mice (b). similarly, P123H βs tg mice had less frequency of crossing the goal (c). Data are shown as the mean ± s.e.m. (n = 7–11). *P < 0.05, **P < 0.01 
versus non-tg mice. (d) Home cage test showing decreased spontaneous activities in P123H βs tg mice (line C) compared with non-tg littermates at 6 
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video tracking system. ‘Awaken’ is the end of sleep during this period. Data are shown as mean ± s.e.m. (n = 7). *P < 0.05, **P < 0.01 versus non-tg mice.  
(e) The rotarod treadmill test showing impaired motor performance in P123H βs tg mice compared with non-tg littermates (nonTg) at different ages. 
Data are shown as mean ± s.e.m. (n = 8–10). *P < 0.05, **P < 0.01 versus non-tg mice.ARTICLE
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paraffin for preparation of 4 µm serial sections for analysis. Free-floating brain sec-
tions were prepared by transcardiac perfusion with ice-cold saline, followed by 4% 
paraformaldehyde or Zamboni’s solution containing glutaraldehyde. Serial sections 
of 40-µm thickness were then prepared. For the hippocampus and cortex, sagittal 
sections ~1.5 mm lateral to the midline or coronal sections ~1.5 mm posterior 
to the bregma, were used. For the striatum and globus pallidus, sagittal sections 
~1.5 mm lateral to the midline or coronal sections ~0.5 mm anterior to the bregma 
were used. For the substantia nigra, coronal sections ~2.6 mm posterior to the 
bregma were used. The location of the slice and identification of brain regions were 
determined by comparison to atlas images36.
Northern blot analysis. Total RNA isolated from whole brains was analysed by 
northern blotting, as previously described37. Hybridization was performed using 
32P-P123H βS cDNA labelled by random priming. The filter was reprobed with 
32P-labelled actin cDNA. The intensities of the hybridization bands were measured 
using BioMAX 1D image analysis software (Kodak).
Immunoblot analysis. Mice brains were homogenized in lysis buffer containing 1% 
Triton X-10038 and centrifuged at 100,000 g for 30 min. The supernatants (10 µg) were 
resolved by SDS–PAGE and electroblotted onto nitrocellulose membranes. The mem-
branes were blocked with 3% bovine serum albumin in Tris-buffered saline (TBS) plus 
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Figure 4 | Non-apoptotic neurodegeneration in bigenic mice overexpressing P123H S and S. Hippocampus (hippo) CA3 and cortex (cort) of 9-month-
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and bigenic, bi. (a, b) Immunohistochemistry of pc-Jun (a) and c-Fos (b). Representative images of bigenic mice and nonTg littermates are shown. scale 
bar = 50 µm. The graph shows quantification of the pc-Jun-positive cell count in 180×180 µm2 areas. Data are shown as mean ± s.e.m. (n = 5 for a, n = 8 for b). 
**P < 0.01 versus non-tg mice. (c) Evaluation of neurodegeneration by FJC staining. Representative images of the hippocampus from bigenic mice and from 
other littermates are shown (four figures in the upper panel). FJC-positive cells were observed in bigenic mice and to a lesser extent in αs tg mice (arrows). 
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figures are shown. scale bar = 50 µm. (f) Appearance of dark degenerating neurons in the hippocampus and cortex of bigenic mice, but not in nonTg brains, in Em.   
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0.2% Tween 20, followed by incubation with primary antibodies in TBS containing  
3% bovine serum albumin. After washing, the membranes were further incu-
bated with secondary antibody conjugated with horseradish peroxidase in TBS 
(1:5,000~10,000). Finally, the target proteins were visualized with the ECL plus system 
(GE Healthcare), followed by quantification using BioMAX 1D image analysis software.
Immunohistochemistry and immunofluorescence. Immunohistochemistry 
was performed as previously described7. Briefly, paraffin sections were autoclaved 
in 0.01 M citrate buffer (pH 6.0) to retrieve antigen. Both paraffin and free-float-
ing sections were then immersed in 0.3% hydrogen peroxide in methanol and 
incubated in 5% normal goat or rabbit serum for blocking. Sections were incubated 
with primary antibodies overnight at 4 °C, followed by detection with biotinylated 
secondary antibodies and the Avidin–Biotin Complex Kit (Vector Laboratories).  
A positive reaction was detected using diaminobenzidine tetrahydrochloride  
containing 0.001% hydrogen peroxide. The results from at least seven images of 
serial sections for each mouse were used and an average value was calculated.
Cells were counted and optical densities were measured in some immuno-
histochemistry experiments. Stereological analysis was conducted with MCID 
image analysis software (InterFocus Imaging) for NeuN-immunoreactive cells in 
the hippocampal CA3 region and cerebral cortex and for TH-immunoreactive 
cells in the substantia nigra, as previously reported39,40. In brief, digital images  
of NeuN- and TH-immunoreactive neurons were acquired at ×50 magnification 
on an Olympus microscope fitted with a video camera (Olympus). A counting 
frame created by the MCID image analysis software was systemically passed over 
the outlined CA3, cerebral cortex areas and substantia nigra pars compacta.  
The neurons were counted as they appeared within the counting frame.  
The average neuron density was obtained by totalling the number of neuron 
profiles and dividing by the calculated area41,42. As for P123H βS-immunoreactive 
cells in the globus pallidus, positive cells with a diameter of  > 3 µm were  
selectively counted. For phospho-c-Jun- and c-Fos-immunoreactive cells,  
counting was conducted in areas of 180×180 µm2 in the hippocampus and cortex. 
For TH-immunoreactive fibres in the striatum, the average optical densities were 
evaluated as previously reported40.
Immunofluorescence was performed as previously described7. Both paraf-
fin and free-floating sections were incubated with primary antibodies, followed 
by Alexa Fluor-conjugated secondary antibodies (Invitrogen). FJC staining was 
performed according to the manufacturer’s instructions (Chemicon). Slides were 
observed by laser scanning confocal microscopy7.
Electron microscopy. EM was performed as previously described with modifica-
tions15. The mice were deeply anaesthetized and killed by cardiac perfusion using 
ice-cold saline, followed by 2% paraformaldehyde and 2% glutaraldehyde. Brain 
tissues were post-fixed with 1% osmium tetroxide, followed by dehydration and 
embedding in Quetol 812 (Nisshin EM). Ultrathin sections were cut, stained with 
uranyl acetate and lead nitrate and observed using a Hitachi H-7650 electron micro-
scope (Hitachi) equipped with a CanoScan 9900F digital imaging system (Canon).
Behaviour tests. Learning and memory were analysed with a Morris water maze 
test, as previously described, with modifications43. A circular pool (diameter 1.5 m, 
height 30 cm, temperature 23 ± 1°C) was filled with water containing non-fat dry 
milk. The escape platform (diameter 10 cm) was located in the centre of one of the 
quadrants of the pool. To habituate mice to the water, the mice were pre-trained 
1 day before starting the training session. Each mouse was placed on the visible 
platform, forced to jump into the water, allowed to swim for 60 s and then guided 
to the escape platform. This procedure was repeated twice for each mouse. During 
the training session, mice were trained to find the platform submerged 1 cm below 
the water surface. If the mouse failed to find the platform within 60 s, it was guided 
to the platform and allowed to remain there for 15 s. Mice received two trials per 
day and were trained for 10 days. On the last day of training, the probe test was 
performed to measure the searching behaviour in the target quadrant (quadrant 
where the platform was located during training) and platform area (the area where 
the platform was located) for 60 s. A video tracking system (Topscan; Clever  
System) was used to analyse the escape latency and swim path.
To evaluate the spontaneous behaviour of mice, a home cage test was per-
formed as previously described44 with modifications. One day before starting 
the test, mice were isolated and put into the test cage. A paper sheet was used as 
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bedding material instead of sawdust for this test to prevent mice hiding in sawdust 
during recording. The recorded video during the dark phase (1900–0700 hours) 
was analysed using Home cage scan software (Clever System). The behavioural 
definitions, including ‘Pause’, ‘Sleep’, ‘Twitch’, ‘Awaken’, ‘Groom’, ‘Sniff’, ‘Rear up’ and 
‘Hang Vertically’, are described elsewhere44.
To measure locomotor activity, the rotarod test was performed as previously 
described7. Briefly, on the first day, mice were trained for three trials: the first one 
at 5 r.p.m., the second at 10 r.p.m. and the third at 20 r.p.m. On the second day, 
mice were tested for seven trials. Mice were placed individually on the rod and the 
speed of rotation was increased from 0 to 40 r.p.m. over 240 s. The length of time 
mice remained on the rod was recorded and the last four trials were averaged as a 
measure of motor function.
TUNEL assay. TUNEL staining was performed using the In Situ Cell Death Detec-
tion Kit POD (Roche) according to the manufacturer’s instructions. For a positive 
control, the section was incubated with 10 U ml − 1 DNase I (Sigma) for 10 min at 
room temperature.
Dopamine enzyme-linked immunosorbent assay. Dopamine concentrations 
were measured using a Dopamine Research ELISA Kit according to the manufac-
turer’s instructions (Labor Diagnostika).
Statistics. Data are presented as mean ± s.e.m. Statistical differences were deter-
mined by either two-tailed t-test or analysis of variance, followed by a post-Fisher’s 
protected least significant difference test, with P < 0.05 considered to indicate a 
significant difference. 
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